Indication | Indication | Discovery | Pre-clinical | Clinical trial | Status | |||
---|---|---|---|---|---|---|---|---|
1 | 2 | 3 | ||||||
Major Depression Disorder | HEMP-001 (Candidate substance H20-01) |
|
US FDA Clinical 2a IND Approved |
|||||
Autism Spectrum Disorder | TBD |
|
||||||
Atopic Dermatitis | HEMP-001 (Candidate substance H20-01) |
|
||||||
Low Anterior Resection Syndrome |
HEMP-002 (Candidate substance H1036) |
|
AUS HREC Clinical 2a Approved |
|||||
Cancer-Induced Diarrhea |
|
|||||||
Chronic Obstructive Pulmonary Disease |
HEMP-003 (Candidate substance H792) |
|
||||||
Non-Alcholic Fatty Liver Disease |
TBD |
|
||||||
Type 2 Diabetes | TBD |
|
||||||
Constipation (in Children) | TBD |
|
Product name | Partner company | Contract | Product development | Trial production | Commercialization |
---|---|---|---|---|---|
BWI Immunity | A** |
|
|||
Zeta Bio (B-active) | C** |
|
|||
E. Faecium HAC233 | L** |
|
|||
MyLAB by NUTRILITE | A** |
|
|||
Customized lactic acid bacteria | Our company’s new brand |
|